---
title: "Using AI for drug evaluation? OpenAI is in talks with the FDA"
description: "According to reports, the FDA is in talks with OpenAI about using AI in drug evaluation to shorten the time for drug approval and market launch. This initiative signifies a potential transformation in"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/239247367.md"
published_at: "2025-05-08T03:34:02.000Z"
---

# Using AI for drug evaluation? OpenAI is in talks with the FDA

> According to reports, the FDA is in talks with OpenAI about using AI in drug evaluation to shorten the time for drug approval and market launch. This initiative signifies a potential transformation in the drug approval process, but it also raises concerns about data security, model reliability, and regulatory frameworks

FDA Embraces AI: Drug Approval Accelerator or Risk Exposure?

According to media reports on Wednesday, the U.S. Food and Drug Administration (FDA) is in talks with OpenAI to **discuss the use of artificial intelligence in drug evaluation, aiming to shorten the time for drug approval and market entry.**

The media cited sources familiar with the matter, stating that a small team from OpenAI has met with the FDA several times in recent weeks, along with two individuals related to the DOGE department. **They are discussing a project called cderGPT, which may stand for "Center for Drug Evaluation and Research GPT."**

Reports indicate that FDA's first AI officer, Jeremy Walsh, is leading these discussions, but no formal contract has been signed yet.

Meanwhile, on Wednesday, FDA Commissioner Marty Makary questioned on the X platform:

> “Why does it take more than 10 years for a new drug to hit the market? Why aren’t we modernizing with AI and other technologies? We just completed our first AI-assisted product science review, and this is just the beginning.”
> 
> ## FDA Actively Exploring AI Applications

The existing review process at the FDA typically takes about a year, but the agency has various mechanisms to accelerate the approval timeline for promising drugs, including fast track designation and breakthrough therapy designation.

In recent years, the FDA has also been advancing its own research into potential uses of AI. In December 2023, the agency posted a job advertisement for researchers aimed at developing large language models for internal use.

In January of this year, OpenAI announced ChatGPT Gov, a self-hosted version of the chatbot compliant with government regulations. The startup also stated that it is working to obtain FedRAMP moderate and high-level certifications for ChatGPT Enterprise, which would allow it to handle sensitive government data.

## Policy Guidance, Review Details, Information Authenticity... Support and Concerns Coexist

Former FDA Commissioner Robert Califf told the media that **the agency's review teams have been using AI for years, and it is important to focus on the specific details of AI-assisted reviews**:

> “Understanding which parts of the review are 'AI-assisted' and what that means will be interesting.”
> 
> “There has always been a demand to shorten review times, and there is a broad consensus that AI can help.”

Rafael Rosengarten, CEO of precision oncology company Genialis and co-founder of the Healthcare AI Alliance, expressed support for automating certain tasks related to drug reviews, but emphasized the need for policy guidance around the types of data used to train AI models and model performance.

A former FDA employee pointed out that **the tendency of AI models to fabricate convincing information raises questions about the reliability of such chatbots**, “Who knows how reliable this platform will be for these review tasks?” PhRMA spokesperson Andrew Powaleny believes:

> "It is crucial to ensure timely review of the safety and efficacy of drugs. While AI is still developing, **utilizing it requires a thoughtful, risk-based approach that is patient-centered**."

### Related Stocks

- [OpenAI.NA - OpenAI](https://longbridge.com/en/quote/OpenAI.NA.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| OpenAI 高管：工程师变成 “魔法师”，AI 将开启新一轮创业狂潮 | OpenAI 内部曝光：95% 工程师已用 AI 编程，代码审查全由 Codex 接管！负责人 Sherwin Wu 预言，未来两年模型将具备数小时长任务处理能力，工程师正变为指挥智能体的 “巫师”。随着模型吞噬中间层，为 “超级个体” 服 | [Link](https://longbridge.com/en/news/275998627.md) |
| Anthropic 按 3800 亿美元估值敲定 300 亿美元融资 | Anthropic 已完成最新的融资交易，从投资者处筹集 300 亿美元资金，融资后估值达到 3800 亿美元（含本轮融资金额），这进一步增强了这家人工智能公司在与劲敌 OpenAI 竞争中的实力。 | [Link](https://longbridge.com/en/news/275804797.md) |
| 科技 IPO 预期升温，但华尔街的主战场已转向债市？ | 尽管 SpaceX、OpenAI 等明星公司 IPO 前景备受关注，美国科技资本市场的重心已实质性转向债务融资。为支撑 AI 基建，全球科技债发行规模预计今年逼近 1 万亿美元，Alphabet、Oracle 等巨头密集发债，Meta、亚马 | [Link](https://longbridge.com/en/news/275770702.md) |
| 加拿大宣布新国防工业战略，注重国内制造以重获战备能力 | 加拿大总理卡尼于 2 月 17 日宣布新的国防工业战略，设定未来十年目标，包括将 70% 的国防合同授予本国企业，旨在实现国内采购和维护大部分军事装备。 | [Link](https://longbridge.com/en/news/276178964.md) |
| OpenClaw 之父爆猛料：Meta 和 OpenAI 跪着抢人，小扎亲自求收购 | 在一场重磅播客访谈中，OpenClaw 之父 Peter Steinberger 透露，Meta 的扎克伯格和 OpenAI 的 Sam Altman 都在积极拉拢他，甚至扎克伯格亲自表示对 OpenClaw 的赞赏。两大科技巨头同时争抢人 | [Link](https://longbridge.com/en/news/275962731.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.